摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Fluocortolone monohydrate | 910908-82-6

中文名称
——
中文别名
——
英文名称
Fluocortolone monohydrate
英文别名
(6S,8S,9S,10R,11S,13S,14S,16R,17S)-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one;hydrate
Fluocortolone monohydrate化学式
CAS
910908-82-6
化学式
C22H31FO5
mdl
——
分子量
394.5
InChiKey
XMXIGEQXHQRVHJ-ABJXWZFZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.81
  • 重原子数:
    28
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    75.6
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • Tissue reactive compounds and compositions and uses thereof
    申请人:Angiotech International AG
    公开号:US20040219214A1
    公开(公告)日:2004-11-04
    A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.
    一种组合物包括一种合成聚合物,可选地存在药物,并且该聚合物包括多个活性基团。这些多个活性基团与动物组织上存在的功能性反应,因此在将聚合物注射到组织中时,聚合物与组织结合。或者,这些多个活性基团与非生物表面上存在的功能性反应,聚合物将与该表面结合,例如增加表面的润滑性。当组合物中存在药物时,药物将被传递到聚合物附着的部位。
  • Soft tissue implants and anti-scarring agents
    申请人:Hunter L. William
    公开号:US20050142162A1
    公开(公告)日:2005-06-30
    Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
    软组织植入物(例如乳房、胸肌、下巴、面部、唇部和鼻部植入物)与抗瘢痕剂结合使用,以抑制动物体内植入物放置时可能发生的瘢痕形成。
  • Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases
    申请人:Combinatorx, Incorporated
    公开号:EP2070550A1
    公开(公告)日:2009-06-17
    The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.
    本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶,治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。
  • Drug delivery from rapid gelling polymer composition
    申请人:ANGIOTECH INTERNATIONAL AG
    公开号:EP2181704A2
    公开(公告)日:2010-05-05
    Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in prevention of surgical adhesions.
    本发明公开了一些组合物,这些组合物由两部分聚合物组成,在混合在一起时可迅速形成共价连接,从而实现药物输送。当需要快速粘附组织和形成凝胶并同时给药时,这种组合物特别适合用于各种与组织相关的应用。例如,这种组合物可用作组织密封剂、促进止血、实现组织粘合、提供组织增量以及防止手术粘连。
  • Methods, compositions, and kits for the treatment of ophthalmic disorders
    申请人:CombinatoRx, Inc.
    公开号:EP2218442A1
    公开(公告)日:2010-08-18
    The invention features methods, compositions and kits comprising a corticosteroid and a non-steroidal immunophilin-dependent immunosuppressant for treating an ophthalmic disorder in a patient, wherein at least one of said corticosteroid and said non-steroidal immunophilin-dependent immunosuppressant is present at a low concentration, in particular wherein said corticosteroid is prednisolone acetate and said non-steroidal immunophilin-dependent immunosuppressant is cyclosporine A.
    本发明的特征是包含皮质类固醇和非类固醇免疫嗜血素依赖性免疫抑制剂的方法、组合物和试剂盒,用于治疗患者的眼科疾病、其中,所述皮质类固醇和所述非类固醇免疫嗜血素依赖性免疫抑制剂中至少有一种以低浓度存在,特别是所述皮质类固醇醋酸泼尼松龙,所述非类固醇免疫嗜血素依赖性免疫抑制剂环孢素 A。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B